NORA: A Nephrology-Oriented Representation Learning Approach Towards Chronic Kidney Disease Classification
Mohammad Abdul Hafeez Khan, Twisha Bhattacharyya, Omar Khan, Noorah Khan[0.1cm], Alina Aziz Fatima Khan, Mohammed Qutub Khan, Sujoy Ghosh Hajra, [0.2cm] Florida Institute of Technology, USA, [0.1cm] Edgewood Jr./Sr. High School, USA Shadan Institute of Medicine Sciences, India, [0.1cm] Riverside Nep · 2025
Read NORA: A Nephrology-Oriented Representation Learning Approach Towards Chronic Kidney Disease Classification by Mohammad Abdul Hafeez Khan, Twisha Bhattacharyya, Omar Khan, Noorah Khan[0.1cm], Alina Aziz Fatima Khan, Mohammed Qutub Khan, Sujoy Ghosh Hajra, [0.2cm] Florida Institute of Technology, USA, [0.1cm] Edgewood Jr./Sr. High School, USA Shadan Institute of Medicine Sciences, India, [0.1cm] Riverside Nep (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2509-12704.txt.
Introduction
Chronic kidney disease hides for years, and the blood and urine markers that expose it are often missing in ordinary clinic visits. Mohammad Abdul Hafeez Khan and six co-authors test in 2025 whether routine non-renal information, demographics, other conditions, and basic urine findings, can flag the disease anyway.
Their approach, NORA, first learns separating patient representations with supervised contrastive learning on clinic records, then hands those features to a random forest classifier. Class separation and overall accuracy improve, with the clearest gains in the early-stage cases that matter most. A public kidney dataset confirms the method travels to a different patient population.
Catalog record
| CREATOR | Mohammad Abdul Hafeez Khan, Twisha Bhattacharyya, Omar Khan, Noorah Khan[0.1cm], Alina Aziz Fatima Khan, Mohammed Qutub Khan, Sujoy Ghosh Hajra, [0.2cm] Florida Institute of Technology, USA, [0.1cm] Edgewood Jr./Sr. High School, USA Shadan Institute of Medicine Sciences, India, [0.1cm] Riverside Nep |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2509-12704
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
NORA: A Nephrology-Oriented Representation Learning Approach Towards Chronic Kidney Disease Classification Mohammad Abdul Hafeez Khan, Twisha Bhattacharyya, Omar Khan, Noorah Khan[0.1cm], Alina Aziz Fatima Khan, Mohammed Qutub Khan, Sujoy Ghosh Hajra, [0.2cm] Florida Institute of Technology, USA, [0.1cm] Edgewood Jr./Sr. High School, USA Shadan Institute of Medicine Sciences, India, [0.1cm] Riverside Nephrology Physicians, USA Abstract Chronic Kidney Disease (CKD) affects millions of people worldwide, yet its early detection remains challenging, especially in outpatient settings where laboratory-based renal biomarkers are often unavailable. In this work, we investigate the predictive potential of routinely collected non-renal clinical variables for CKD classification, including sociodemographic factors, comorbid conditions, and urinalysis findings. We introduce the Nephrology-Oriented Representation leArning (NORA) approach, which combines supervised contrastive learning with a nonlinear Random Forest classifier. NORA first derives discriminative patient representations from tabular EHR data, which are then used for downstream CKD classification. We evaluated NORA on a clinic-based EHR dataset from Riverside Nephrology Physicians. Our results demonstrated that NORA improves class separability and overall classification performance, particularly enhancing the F1-score for early-stage CKD. Additionally, we assessed the generalizability of NORA on the UCI CKD dataset, demonstrating its effectiveness for CKD risk stratification across distinct patient cohorts. I Introduction Chronic Kidney Disease (CKD) is a progressive condition characterized by the gradual loss of kidney function over time. Affecting an estimated 35.5 million individuals in the United States alone, CKD is often asymptomatic in its early stages and may go undetected until significant renal damage has occurred. This delayed diagnosis frequently leads to poor health outcomes, including cardiovascular disease, hospitalization, and premature mortality [ 1 ] . Glomerular filtration rate (GFR) is regarded as the most reliable indicator of kidney function, signaling how effectively the kidneys filter waste from the blood. While GFR can be directly measured using inulin or other exogenous filtration markers, this approach is rarely used in clinical practice due to cost and complexity. As a result, clinical guidelines for CKD management rely heavily on the estimated GFR (eGFR), which is derived from serum creatinine levels, adjusted for age, sex, and race, and serves as a widely accepted indicator of renal function [ 2 ] . Based on the eGFR value, patients are categorized into six stages of CKD. Stages 1–2 (eGFR \geq 60) indicate normal to mildly reduced kidney function. Stage 3 is divided into 3a (eGFR 45–59) and 3b (30–44), reflecting moderate decline. Stage 4 (eGFR 15–29) indicates severe loss of kidney function, and Stage 5 (eGFR < 15) corresponds to kidney failure. Finally, End-Stage Renal Disease (ESRD) refers to the phase where patients require long-term dialysis or post-transplant care. While eGFR serves as the clinical standard for CKD staging, a range of routinely collected clinical variables from electronic health records (EHRs) also offer valuable predictive signals. Such information is particularly useful in outpatient or resource-limited settings where laboratory-based renal biomarkers may not be readily available. These variables are typically captured during patient intake, follow-up visits, or chronic disease management workflows. They include sociodemographic factors (such as age, sex, and race), anthropometric measures (including height and weight), and chronic health conditions such as hypertension, diabetes mellitus, dyslipidemia, and diabetic nephropathy—among the most common contributors to kidney disease globally [ 3 , 4 , 27 , 28 ] . In addition, urinary abnormalities such as proteinuria and hematuria, when detected through routine urinalysis, can serve as early indicators of renal injury and are frequently incorporated into clinical assessments of kidney health [ 5 ] . While these features do not directly measure renal filtration capacity, they are well-established risk factors for CKD and offer pathways for identifying individuals at elevated risk. Prior works [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ] have applied machine learning (ML) methods to classify CKD, most notably using the widely studied UCI CKD dataset [ 26 ] . While these models have achieved strong performance, they primarily rely on variables such as serum creatinine, blood urea, and hemoglobin—direct indicators of kidney function that may not always be accessible. In contrast, our work evaluates the predictive value of renal biomarker-agnostic clinical features for CKD classification. We leverage a clinic-based EHR dataset from Riverside Nephrology Physicians (RNP), which is a community-based, single-specialty practice in urban Southern California focused on the diagnosis and management of kidney diseases. The RNP dataset includes de-identified patient records with CKD stage labels, along with sociodemographic, anthropometric, and routinely observed clinical variables. To establish a baseline for the RNP dataset, we first applied standard widely used ML algorithms. While these models achieved reasonable F1-score and accuracy, they struggled with two key challenges: the imbalanced distribution of the data and the complex, nonlinear relationships among clinical variables. In particular, linear and distance-based models failed to capture nuanced feature interactions, while even more flexible models like tree ensembles showed relatively low sensitivity to early-stage CKD. These limitations highlighted the need for a more expressive modeling approach. Contributions. We propose the N ephrology- O riented R epresentation le A rning ( NORA ) approach, which applies supervised contrastive learning (SCL) with a nonlinear classifier to tabular nephrology data. NORA learns semantically meaningful representations from the clinical variables, improving CKD class separability in the latent space. To the best of our knowledge, this is the first application of SCL to tabular renal health records. We observe that the commonly used logistic regression (LR) with SCL, as proposed by Khosla et al. [ 25 ] , underperforms in this setting due to complex feature interactions among patients. In contrast, using a Random Forest classifier significantly improves performance, especially on the early-stage CKD in the imbalanced RNP dataset—achieving a 10.1% gain in F1-score compared to the SCL+LR baseline. Additionally, we evaluate NORA on the publicly available UCI CKD dataset [ 26 ] , demonstrating its generalizability across distinct patient cohorts and clinical variable distributions. II Related Works Traditional approaches to chronic kidney disease (CKD) risk prediction have relied on clinical equations and statistical models that incorporate laboratory-based biomarkers such as serum creatinine or estimated glomerular filtration rate (eGFR) [ 5 , 6 , 7 , 8 , 9 , 10 ] . While widely used, these methods have notable limitations. For instance, Dharmaratne et al. [ 5 ] highlight the insensitivity of serum creatinine in early-stage detection, and Aoki et al. [ 9 ] critique the Kidney Failure Risk Equation (KFRE) for its focus on late-stage outcomes. To address these limitations, machine learning (ML) has emerged as a powerful tool across domains [ 19 , 20 ] , including healthcare, where it has enabled advances in clinical decision support, and risk prediction [ 21 , 22 , 23 ] . In the context of CKD, recent studies have applied ML techniques for disease classification and progression prediction using clinical and demographic features [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ] . More specifically, these methods have been used to enhance early detection and risk stratification using EHR data [ 7 ] , predict progressive kidney function decline through supervised learning [ 8 ] ,